Noxafil “Approvable” Response To Be Submitted In 2006, Schering Says

Schering-Plough expects to submit a complete response to FDA's "approvable" letter seeking additional data on the oral triazole antifungal Noxafil (posaconazole) next year, Exec VP-Global Development Thomas Koestler said during Schering-Plough's R&D update Nov. 1